Calliditas Year-end report, January - December 2023

"In December we were granted full approval by the FDA for TARPEYO - a crowning achievement after many years of striving to bring an approved disease modifying treatment to patients with primary IgAN." "In December we were granted full approval by the FDA for TARPEYO - a crowning achievement after many years of striving to bring an approved disease modifying treatment to patients with primary IgAN." CEO Renée Aguiar-Lucander OUTLOOK FOR 2024 Calliditas expects continued revenue...

"In December we were granted full approval by the FDA for TARPEYO - a crowning achievement after many years of striving to bring an approved disease modifying treatment to patients with primary IgAN."

CEO Renée Aguiar-Lucander

OUTLOOK FOR 2024

Calliditas expects continued revenue growth:

Total net sales are estimated to be USD 150-180 million for the year ending December 31, 2024

INVESTOR PRESENTATION

February 21, 2024, 14:30 CET

Link to webcast: https://ir.financialhearings.com/calliditas-therapeutics-q4-report-2023

To participate via conference call register via this link: https://conference.financialhearings.com/teleconference/?id=50046870

For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com

The information in the press release is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact person set out above, on February 21, 2024, at 07:00 a.m. CET.

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/calliditas-year-end-report-january--december-2023-302066986.html